Global demand for Penile Cancer Market was valued at approximately USD 19.8 billion in 2019, and is expected to generate revenue of around USD 32.1 billion by end of 2026, growing at a CAGR of around 7.1 % between 2020 and 2026
According to the report, global demand for Penile Cancer market was valued at approximately USD 19.8 billion in 2019, and is expected to generate revenue of around USD 32.1 billion by end of 2026, growing at a CAGR of around 7.1 % between 2020 and 2026.
Prostate cancer, testicular cancer, and penile cancer are specific to male related cancers. Prostate cancer is the most prevalent in males with respect to penile cancer. Penile cancer in which cancerous cell form in penis. Penile cancer is commonly associated with HPV (human papiloma virus) & HIV (human immune deficiency virus). Other causes of penile cancer are tobacco, poor hygiene, age & other skin problem. Symptoms includes are lumps, bleeding, redness etc.
According to the U.S National Cancer Institute study show 40% of all penile cancer as a result of HPV infections, whereas HIV patients exhibit eight time increased risk of penile cancer. Hence penile cancer rate is high in developing countries like south Asia, South America and Africa. Penile cancer majorly classify into squamous cell carcinoma, intraepithelial neoplasia, bowenoid papulosis and invasive carcinoma of the penis. Majority of penile cancer patients have exhibited squamous cell carcinoma. Initially penile cancer is diagnosed by physical examination of penis followed by biopsy of outer growth i.e. Wart or skin abscess. Chemotherapy, antiviral therapy and surgical excision are common mode for the treatment of penile cancer.
Penile cancer treatment market is driven by increasing incidence of penile cancer across globe. Furthermore, medicines coupled with advance technology & economical treatments are the major driven factor for increase in penile cancer treatment market. However, lack of awareness, healthcare literacy, and commercially less availability of drugs are major restraining factors that is expected to curb the market growth in the near future. Nonetheless, ongoing research and development in the healthcare sector coupled with advancement in medical technologies, literacy rate are expected to open growth avenues for the market over the years.
The report covers forecast and analysis of the penile cancer treatment market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Million). To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the penile cancer treatment has also been included in the study. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate and general attractiveness.
The report provides detailed segmentation of the penile cancer treatment market based on type of disease, therapy, diagnostic test and regional segment. The penile cancer type’s market segment held the largest market share in 2015.
Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Demand has been analyzed and forecast based on the current trends for the period of six years. North America was the leading segment of penile cancer treatment market followed by Europe in 2015, as in these regions the number of reported cases are high in number, and so is the affordability of drugs. The penile cancer treatment market is expected to witness the highest growth in the South America & Asia-Pacific region in the coming years due to poor hygiene standards, large number of HIV patient population.
The report covers scenario including the company overviews, financial revenues of the key participants. Key players included in report are Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Novartis AG, and others.
|Historic Years||2016 - 2020|
|Forecast Years||2021 - 2028|
|Segments Covered||By Product Type, By Application, and By End Use|
|Forecast Units||Value (USD Billion), and Volume (Units)|
|Quantitative Units||Revenue in USD million/billion and CAGR from 2021 to 2028|
|Regions Covered||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World|
|Countries Covered||U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others|
|Number of Companies Covered||10 companies with scope for including additional 15 companies upon request|
|Report Coverage||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.|
|Customization Scope||Avail customized purchase options to meet your exact research needs.|
This report segments the penile cancer treatment market are:-
Penile Cancer Treatment Market: Type Analysis
Penile Cancer Treatment Market: Type Of Therapy Segment Analysis
Penile Cancer Treatment Market: Diagnostic Test Segment Analysis
Penile Cancer Treatment Market: Regional Segment Analysis
Request the coronavirus impact analysis across industries and markets